Expertise in
5
conditions

Chunde M. Bao

Shanghai, CN 
Expertise in
5
conditions
Shanghai, CN 

Overview

Chunde Bao practices practicing medicine in Shanghai, China.

Bao is highly rated in 5 conditions, according to our data. Their clinical expertise encompasses Arthritis, Rheumatoid Arthritis (RA), Ankylosing Spondylitis, and Polymyositis.

They are actively involved in clinical research, co-authoring 50 peer reviewed articles and participating in 6 clinical trials.

Locations

Shanghai, China
Other Locations
Beijing, 100039, China
145 Middle Of Shandong Road, PR China, Huangpu, 200001, China
180 Fenglin Road, Zhongshan, 200032, China
Tianjin, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Multicenter, Randomized, Double-blind, Controlled Phase II Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin®) for the Treatment of Knee Osteoarthritis
A Multicenter, Randomized, Double-blind, Controlled Phase II Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin®) for the Treatment of Knee Osteoarthritis
Enrollment Status: Completed
Publish Date: August 01, 2023
Intervention Type: Biological
Study Drug: Allogeneic Adipose-Derived Mesenchymal Stem Cells (adMSC)
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase I, Randomized, Single-centered, Double-blinded Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis
A Phase I, Randomized, Single-centered, Double-blinded Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis
Enrollment Status: Completed
Publish Date: September 13, 2018
Intervention Type: Biological
Study Phase: Phase 1
A PhaseⅡb, Randomized, Double-blinded, Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis
A PhaseⅡb, Randomized, Double-blinded, Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis
Enrollment Status: Completed
Publish Date: November 17, 2017
Intervention Type: Biological
Study Phase: Phase 2
View 5 Less Clinical Trials

50 Total Publications

ANK1 and EPB41 Variants and The Risk of Glucocorticoid-Induced Osteonecrosis.
ANK1 and EPB41 Variants and The Risk of Glucocorticoid-Induced Osteonecrosis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: November 06, 2025

Frequently Asked Questions about Chunde M. Bao

Is Chunde M. Bao a top-rated expert for Arthritis?

MediFind is an objective health platform that identifies experts based on real-world data. Chunde M. Bao is classified as an Advanced expert for Arthritis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Chunde M. Bao participate in research or clinical trials?

Yes. Chunde M. Bao has published 50 articles and abstracts on conditions like Arthritis. You can view a list of Chunde M. Bao's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Bao's expertise for a condition
ConditionClose
      View All 13 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile